UroGen Pharma Ltd.
General ticker "URGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.2B (TTM average)
UroGen Pharma Ltd. follows the US Stock Market performance with the rate: 57.3%.
Estimated limits based on current volatility of 3.2%: low 35.40$, high 37.89$
Factors to consider:
- Total employees count: 291 (+23.8%) as of 2025
- Top business risk factors: Failure to obtain approval, Product development failure, Insufficient capital, Commercialization challenges, Supply chain disruptions
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.55$, 36.61$]
- 2026-12-31 to 2027-12-31 estimated range: [13.06$, 31.28$]
Financial Metrics affecting the URGN estimates:
- Negative: with PPE of -7.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Operating cash flow
- Negative: Shareholder equity ratio, % of -52.62 <= 7.04
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: 1.34 < Inventory ratio change, % of 3.78
Short-term URGN quotes
Long-term URGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $82.71MM | $90.40MM | $109.79MM |
| Operating Expenses | $148.25MM | $187.18MM | $234.65MM |
| Operating Income | $-65.54MM | $-96.78MM | $-124.86MM |
| Non-Operating Income | $-32.79MM | $-27.26MM | $-28.55MM |
| Interest Expense | $14.71MM | $12.52MM | $15.35MM |
| R&D Expense | $45.61MM | $57.15MM | $67.11MM |
| Income(Loss) | $-98.32MM | $-124.04MM | $-153.42MM |
| Taxes | $3.92MM | $2.83MM | $0.08MM |
| Net Income(Loss)* | $-102.24MM | $-126.87MM | $-153.49MM |
| Stockholders Equity | $-65.21MM | $-8.80MM | $-105.47MM |
| Inventory | $5.67MM | $9.23MM | $16.46MM |
| Assets | $178.31MM | $285.71MM | $200.46MM |
| Operating Cash Flow | $-76.38MM | $-96.77MM | $-162.44MM |
| Capital expenditure | $0.19MM | $0.29MM | $0.29MM |
| Investing Cash Flow | $-0.95MM | $-20.61MM | $61.56MM |
| Financing Cash Flow | $116.93MM | $194.62MM | $39.92MM |
| Earnings Per Share** | $-3.55 | $-2.96 | $-3.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.